Primary Theme · Human Augmentation & Interfaces · Updated 8 May 2026

Biotechnology & Human Enhancement

This page focuses on public-market microcap exposure to human augmentation, neural interfaces, neurostimulation, cognition measurement, medical interfaces, HMI hardware, haptics, edge-AI enablers and the infrastructure sitting around private BCI leaders.

Maturity: Early / ScalingCapital intensity: Medium / HighBest angle: interface infrastructureRisk: financing + clinical timelines

Overview

The direct public-market route into brain-computer interfaces is limited because the highest-profile BCI companies — Neuralink, Synchron, Paradromics and Precision Neuroscience — remain private. That means the investable public-market approach has to be indirect: neuro-navigation, neural electrodes, neurostimulation, cognition measurement, implantable sensors, optics, haptics, force sensors, low-power compute and licensable interface IP.

The uploaded synthesis report reconciles two prior screens using a five-factor framework: thematic purity, picks-and-shovels role, revenue quality, profitability or path to profitability, and catalyst density. This page turns that synthesis into the Futurology Hub format.

EarlyBCI public-market maturity

StrongInterface infrastructure angle

HighClinical and financing risk

SelectiveMicrocap investability

Stock Table

Synthesised ranking from the uploaded report. Confidence ratings are retained from the report and should be revisited after the May 2026 catalyst cluster.

Rank	Company	Ticker	Sector	One-line thesis	Confidence
1	Cogstate	CGS.AX	Cognition measurement	Profitable digital cognitive-assessment platform embedded in clinical-trial workflows; cleanest quality compounder candidate.	4.5
1	BrainsWay	BWAY	Neurostimulation	Profitable, cash-rich Deep TMS platform growing strongly with high gross margin.	5.0
3	ClearPoint Neuro	CLPT	Neuro-navigation / delivery	Scarce public infrastructure for CNS delivery, neurosurgical precision and BCI-adjacent procedures.	4.3
4	NeuroPace	NPCE	Implantable neurostimulation	Closed-loop brain-stimulation platform with strong gross margin; borderline microcap and not yet profitable.	4.0
5	Ambiq Micro	AMBQ	Edge-AI compute	Always-on AI compute for wearables, hearables, healthcare and edge devices.	3.5
6	ONWARD Medical	ONWD / ONWRY	Neurorestoration / BCI	Most direct listed BCI/neurorestoration exposure via ARC-EX, ARC-IM and ARC-BCI programmes.	3.7
7	electroCore	ECOR	Non-invasive neurostimulation	High-margin vagus nerve stimulation platform; growing but still loss-making.	3.4
8	Tobii	TOBII.ST	HMI hardware	Pure eye-tracking interface bottleneck for XR, healthcare, automotive and research.	3.5
9	Senseonics	SENS	Implantable medical interface	Long-duration implantable CGM platform; financing and competition complicate the case.	3.4
10	CEVA	CEVA	Interface IP	Licensable connectivity, sensor-fusion and edge-AI IP for interface devices.	4.0
11	Interlink Electronics	LINK	Tactile / force sensors	Underfollowed force-sensor and printed-electrode supplier with HMI and robotic-surgery adjacency.	3.5
12	NeuroOne Medical	NMTC	Neural electrodes	True BCI-adjacent electrode supplier with strong growth from a tiny base but fragile balance sheet.	3.4

Value Chain Map

Layer	What it supplies	Representative names	Investment note
Cognition measurement	Digital tests, trial endpoints, brain-health measurement	Cogstate	Best blend of profitability, workflow embedding and thematic relevance.
Neurostimulation platforms	Deep TMS, RNS, vagus nerve stimulation, spinal cord stimulation	BrainsWay, NeuroPace, electroCore, ONWARD, Neuronetics	Most direct revenue exposure, but reimbursement and clinical adoption matter.
Neuro-delivery infrastructure	MRI-guided navigation, CNS delivery, neural electrodes, ablation electrodes	ClearPoint Neuro, NeuroOne	Closest public picks-and-shovels route into future BCI and CNS procedures.
Body-machine medical interfaces	Implantable CGM, remote cardiac monitoring, digital chronic care	Senseonics, Biotricity, DarioHealth	Commercially real but often financing-sensitive and competitively intense.
HMI hardware	Eye tracking, microdisplays, optics, smart glasses, haptics, force sensors	Tobii, Interlink, Kopin, Vuzix, Immersion, Wearable Devices	Important interface layer, but many names have scale, dilution or profitability issues.
Edge-AI enablers	Low-power silicon, licensable IP, eFPGA, neuromorphic compute	Ambiq, CEVA, QuickLogic, BrainChip	Better picks-and-shovels profile, but valuation discipline is essential.

Sub-Themes

Neural interfaces: electrodes, neurosurgical navigation, closed-loop stimulation and BCI-adjacent delivery infrastructure.
Neurostimulation: TMS, RNS, vagus nerve stimulation and spinal-cord stimulation for clinical and performance applications.
Medical interfaces: implantable sensors and body-worn monitoring systems feeding healthcare data platforms.
Human-machine interface hardware: eye tracking, haptics, force sensing, smart-glasses optics and neural-input wearables.
AI-assisted cognition: cognitive testing, in-car assistants, low-power wearable compute and edge AI.

Market Forces

Private BCI leadership: most pure BCI companies remain private, pushing public investors toward infrastructure proxies.
Clinical-trial demand: cognition tools and neuro-delivery systems benefit from pharma and neurotechnology research.
Ageing demographics: neurological disease, chronic disease and brain-health monitoring expand the addressable market.
Wearable AI: always-on sensors need ultra-low-power compute and efficient connectivity.
Financing pressure: the most thematically pure names are often the least financially mature.

Technology Deep Dive

Human augmentation is not one technology. It is a stack that connects biological signals, sensors, stimulation, computation and software. The public-market screen is therefore a proxy basket: cognitive endpoints, neurosurgical infrastructure, stimulation platforms, implantable sensors, optics, haptics and edge-AI silicon.

Technical bottleneck	Why it matters	Public-market angle
Precise CNS delivery	Advanced neurodevices, gene therapies and future BCI procedures require accurate, repeatable access to the brain and spine.	ClearPoint Neuro.
Closed-loop stimulation	Systems that sense and stimulate in response to neural activity are closer to true neural interfaces than simple open-loop devices.	NeuroPace.
Digital cognition endpoints	Brain-health therapeutics and trials need standardised, scalable cognitive measurement.	Cogstate.
Low-power edge AI	Wearables and implantable-adjacent devices cannot rely on power-hungry cloud inference.	Ambiq, CEVA, QuickLogic, BrainChip.
Physical interface layer	Human attention, touch, force and vision need to be translated into machine-readable signals.	Tobii, Interlink, Kopin, Immersion, Wearable Devices.

Company Profiles

1. Cogstate · CGS.AX

Cognition measurement · top-tier quality compounder candidate

Cogstate supplies digital cognitive assessment tools used in clinical research and brain-health measurement. It is not a consumer enhancement story; it is a measurement layer for neurology trials and cognitive endpoints.

Why it matters: profitable, growing, embedded in clinical workflows.
Key data from report: 1H26 revenue $26.9m, NPAT $4.5m, EBITDA margin 24.3%, future contracted revenue $104.9m.
Main risks: clinical-trial delays, customer concentration and backlog conversion.

1. BrainsWay · BWAY

Deep TMS neurostimulation · highest confidence in synthesis

BrainsWay is the cleanest profitable neurostimulation platform in the screen. It sells Deep TMS systems for depression, OCD, smoking addiction and expanding psychiatric indications.

Why it matters: high gross margin, profitability, cash strength and strong growth.
Key data from report: FY25 revenue $52.2m, up 27%; net income $7.6m; gross margin around 75%; 2026 revenue guidance $66m–$68m.
Main risks: reimbursement, procedure volume, competition and lease-model execution.

3. ClearPoint Neuro · CLPT

Neuro-navigation and CNS delivery · key picks-and-shovels name

ClearPoint provides MRI-guided navigation, neurosurgical access and controlled delivery tools for brain and spine procedures. It is one of the best public proxies for the infrastructure required around advanced neurodevices, CNS drug delivery and future BCI-adjacent procedures.

Why it matters: scarce public neuro-delivery infrastructure.
Key data from report: FY25 revenue $37.0m, up 18%; 2026 guidance $52m–$56m; gross margin around 61%.
Main risks: partner trial failures, regulatory timing, funding needs and customer concentration.

4. NeuroPace · NPCE

Closed-loop implantable neurostimulation

NeuroPace offers responsive neurostimulation for epilepsy, plus seizure-data and AI tools. It is one of the closest listed names to true closed-loop neural interface exposure.

Why it matters: scarce public closed-loop brain-stimulation platform.
Key data from report: FY25 revenue $100.0m, up 25%; GAAP gross margin 77.2%; RNS gross margin 81.9%.
Main risks: implant adoption, reimbursement, leverage and regulatory timing.

5. Ambiq Micro · AMBQ

Ultra-low-power edge-AI compute

Ambiq supplies low-power semiconductors, AI runtimes and SDKs for wearables, hearables, healthcare and industrial edge devices. It is a picks-and-shovels compute bottleneck for always-on AI at the body and sensor edge.

Why it matters: strong fit with wearable AI and health edge devices.
Key data from report: FY25 net sales $72.5m; Q4 non-GAAP gross margin 45.5%; Q1 2026 guide $21m–$22m.
Main risks: post-IPO valuation, losses, customer/geography concentration and semiconductor cyclicality.

6. ONWARD Medical · ONWD / ONWRY

Neurorestoration and BCI-adjacent spinal stimulation

ONWARD is the most direct listed exposure to neurorestoration and BCI-linked movement recovery through ARC-EX, ARC-IM and ARC-BCI programmes.

Why it matters: unusually direct human-augmentation exposure.
Key data from report: FY25 revenue €5.4m; net cash €68.1m; runway into Q1 2028 after recent raise.
Main risks: high burn, reimbursement, long clinical timelines and commercial execution.

7. electroCore · ECOR

Non-invasive vagus nerve stimulation

electroCore provides non-invasive vagus nerve stimulation across prescription, pain/wellness and human-performance channels. It is a bioelectronic interface to the vagus nerve rather than a pure BCI.

Why it matters: high gross margin and expanding human-performance channel.
Key data from report: FY25 revenue $32.0m, up 27%; gross margin around 87%; 2026 guide around 30% growth.
Main risks: cash runway, reimbursement, wellness-channel execution and dilution.

8. Tobii · TOBII.ST

Eye tracking and attention computing

Tobii is a pure interface bottleneck: machines interpreting human attention. Its markets include healthcare, XR, automotive, research, training and gaming.

Why it matters: clean HMI exposure, especially for XR and attention-aware systems.
Key data from report: Q1 2026 net sales SEK164m; gross margin improved to 84%; still loss-making.
Main risks: revenue decline, turnaround execution, OEM concentration and financing.

9. Senseonics · SENS

Implantable continuous glucose monitoring

Senseonics provides Eversense 365, a long-duration implantable CGM system. This is a body-machine medical interface between implanted sensor, cloud data and automated insulin ecosystems.

Why it matters: one of the clearer implantable-sensor microcaps.
Key data from report: 2026 revenue guide $58m–$62m; gross margin guide around 50%.
Main risks: Dexcom/Abbott competition, direct-sales execution, reimbursement and dilution/debt complexity.

10. CEVA · CEVA

Interface IP, connectivity and edge-AI licensing

CEVA supplies licensable silicon and software IP for Bluetooth, Wi-Fi, UWB, cellular IoT, sensor fusion, audio, DSP and edge-AI NPUs. It is an interface-stack supplier rather than a medical-device company.

Why it matters: strong picks-and-shovels profile across wearable, hearable, sensor and interface devices.
Key data from report: FY25 revenue $109.6m; GAAP gross margin 88%; 54 licensing agreements in 2025.
Main risks: licensing-cycle lumpiness, royalty dependence and valuation.

Future Scenarios

Bull case: neurostimulation, cognition measurement, body-machine sensors and low-power wearable AI all scale together, while private BCI progress increases demand for public infrastructure proxies.

Base case: the theme grows unevenly. Profitable names such as Cogstate and BrainsWay remain investable, while speculative BCI-adjacent names require smaller sizing and fresh catalyst checks.

Bear case: clinical timelines stretch, reimbursement disappoints, funding conditions tighten and the most thematically pure microcaps dilute shareholders before revenue arrives.

Signals to Watch

May 2026 reporting wave: NeuroPace, NeuroOne, Kopin, BrainsWay, ClearPoint, DarioHealth and ONWARD.
ClearPoint guidance support and Velocity Alpha / partner trial progress.
BrainsWay sustained operating profitability and payer-supported adoption.
ONWARD ARC-EX commercial roll-out and ARC-BCI progress.
NeuroOne cash runway, listing status and partner discussions.
Senseonics Eversense 365 adoption, Europe approval and AID integration.
Ambiq and CEVA design wins converting into revenue and royalties.

Metrics That Matter

Gross margin: separates high-value platforms/IP from low-quality device revenue.
Cash runway: crucial for ONWARD, NeuroOne, Wearable Devices, DarioHealth, Senseonics and similar names.
Revenue quality: contracted backlog, recurring monitoring revenue, royalties and consumables are better than one-off hardware sales.
Clinical/regulatory milestones: FDA clearances, PMA supplements, label expansions and reimbursement decisions.
Customer concentration: pharma trials, OEM programmes and partner-driven channels can create hidden risk.
Valuation against guided revenue: especially important in early-stage loss-making device companies.

Risk Map

Financing risk: the report highlights concentrated financing pressure in NeuroOne, Wearable Devices, DarioHealth, Senseonics and ONWARD.
Profitability trade-off: the most direct neural-interface plays are often loss-making; the profitable names are sometimes less pure.
Clinical risk: trials, regulatory timing and reimbursement can dominate fundamentals.
Commercial adoption: devices need physician uptake, payer support and patient utilisation.
Valuation risk: several edge-AI and optics names already price in large future adoption.
Liquidity risk: OTC, ASX, European and nano-cap names may be difficult to enter or exit cleanly.

Convergence

AI + Healthcare: cognition measurement, AI diagnostics, remote monitoring and clinical workflow automation.
Wearables + Edge AI: Ambiq, CEVA and QuickLogic-style compute/IP for always-on sensing.
Neurotech + Robotics: BCI-driven movement recovery, prosthetics, rehabilitation robotics and human-machine control.
Spatial Computing + HMI: Tobii, Kopin, Vuzix, Interlink and Immersion as interface hardware suppliers.
Biotech + Data Infrastructure: cognition endpoints and neurodevice data streams as clinical-trial infrastructure.

Research Library

Primary input for this page:

Human Augmentation & Interfaces — Public-Market Microcap Screen, Synthesised Report, timestamped 6 May 2026, Europe/London. Uploaded PDF. The report synthesises two prior research screens and reconciles rankings across four sectors.

Internal source mapping from the report:

Top 12 synthesised ranking: page 3.
Neural interfaces, neurostimulation and neuro-delivery infrastructure: pages 5–6.
Wearable and implantable medical interfaces: page 7.
HMI hardware: pages 8–9.
Cognition, AI-HMI and edge-AI enablers: page 10.
Watchlist, catalyst calendar, cross-cutting themes and shortlists: pages 11–16.

Summary

The highest-quality names in this screen are Cogstate, BrainsWay and ClearPoint Neuro. Cogstate is the cleanest cognition-measurement compounder candidate; BrainsWay is the strongest profitable neurostimulation platform; ClearPoint is the best picks-and-shovels neuro-delivery infrastructure name.

The purest public-market human-augmentation exposures — ONWARD Medical, NeuroOne and Wearable Devices — are also the most financing-sensitive. They should be treated differently from the quality shortlist. The better approach is to separate the universe into three baskets: highest-quality compounders, pure picks-and-shovels suppliers, and speculative optionality.

Current working conclusion: Human augmentation is investable, but mostly through infrastructure and interface layers rather than through pure BCI public companies. The best names combine real revenue, balance-sheet resilience and exposure to the tools that future neurotech and body-machine systems will need.